Ask VialBase
Cross-sectional real-world study (Adelphi Disease Specific Programme) · PMID 41965443

Health-Related Quality of Life and Work-Related Outcomes in People with Obesity Treated with Tirzepatide — VialBase Research

Tirzepatide users reported higher SF-36v2 scores than non-medication users

Last updated · 2026 · Gibble TH, Leith A, Harrison L, et al. · Advances in Therapy
Key findings
  • Tirzepatide users reported higher SF-36v2 scores than non-medication users
  • Lower work impairment observed in tirzepatide group vs non-treated group
  • 1,082 people with obesity included (199 tirzepatide, 158 other OMM, 725 non-OMM)
  • First real-world HRQoL data for tirzepatide in obesity population

Summary

This real-world exploratory study from the US cohort of the Adelphi Real World Obesity III Disease Specific Programme examined quality-of-life and work-related outcomes among people with obesity (PwO) on tirzepatide compared to other obesity management medications (OMMs) and non-medicated individuals. Data were collected between October 2023 and January 2025.

Key Findings

  • 1,082 PwO included: 199 on tirzepatide, 158 on other OMMs, 725 not on OMMs
  • Mean age 47 years, 67.4% female
  • Average time on OMM: 7.4 months (tirzepatide group)
  • Tirzepatide users reported higher scores on most SF-36v2 domains compared to non-medicated group
  • Minimal differences in HRQoL between tirzepatide and other OMM groups
  • General trend toward less work impairment in medicated vs non-medicated groups
  • Exploratory/descriptive — no formal hypothesis testing

Relevance to Tirzepatide

This study provides the first published real-world quality-of-life data for tirzepatide in obesity management. While clinical trials focus on weight loss and metabolic endpoints, real-world QoL data matters for treatment adherence, patient satisfaction, and health economic evaluations. The findings suggest tirzepatide users experience quality-of-life benefits consistent with (or slightly better than) other OMMs, supporting its value proposition beyond weight loss alone.

Citation

Gibble TH, Leith A, Harrison L, et al. Health-Related Quality of Life and Work-Related Outcomes in People with Obesity or Overweight Treated with Tirzepatide or Other Obesity Medications. Adv Ther. 2026. doi:10.1007/s12325-026-03580-w.

See Also

View on PubMed · PMID 41965443 →